The Way of the Engineer.... In engineering if you can not find an analytical solution you asymptotically move toward solution through iterative calculations making your error smaller with every cycle and making assumptions. I once talked with Phd (mathematics) guy and he derisively asserted that if in engineering you are within 20% of solution you … Continue reading Comparing Trofinetide and Anavex2-73. This Installment We Try to Estimate RSBQ Score of AVATAR RS-002 From Hearsay and Formulas for Cohen’s d for RSBQ-ACU. All for Rett Syndrome Winning Drug. $AVXL $ACAD
I was asked.... ...to comapre directly the performance of $ACAD Trofinetide to Anavex2-73 in RS-002 Avatar. It took me some time to analyse how to do it, and I found the only possible way at this time to use the data supplied by $ACAD to apply the AUC treatment to its results. The available data … Continue reading RSBQ-AUC, a More Sensitive Measure of Rett Syndrome Data. Now Applied to $ACAD Trofinetide. Ready Comparison to $AVXL Anavex2-73.
I was informed that what market fear is that ..... On Stocktwits I got following message. Let us examine this claim.... We have to asks ourselves what is the p-vlaue and how is it calculated? For the null hypothesis to be true is that large enough number of the values of the sample (Dose cohort) … Continue reading P-values Fears And Jesus Visits The Placebo Arm of AVATAR Rett Syndrome Anavex2-73 $AVXL
Better Does Not Mean More Familiar The first issue I want to discuss is the CGI-I anchoring of RSBQ-AUC, or rather the familiar RSBQ that is here the raw data. If the CGI-I score improves (drops) by one point out of the 3 possible to describe the improvement then the RSBQ scores are accepted for … Continue reading FDA Made $AVXL Change To More Sensitive Measure Of Efficacy-AVATAR Results $AVXL $ACAD